Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults
- 23 September 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 19 (14), 1443-1448
- https://doi.org/10.1097/01.aids.0000183633.06580.8a
Abstract
873140 is a spirodiketopiperazine CCR5 antagonist with prolonged receptor binding and potent antiviral activity in vitro. This study evaluated plasma HIV RNA, safety, and pharmacokinetics following short-term monotherapy in HIV-infected adults. Double-blind, randomized, placebo-controlled multi-center trial. Treatment-naive or experienced HIV-infected subjects with R5-tropic virus, CD4 cell count nadir > 200 × 106 cells/l, viral load > 5000 copies/ml and not receiving antiretroviral therapy for the preceding 12 weeks were enrolled. Forty subjects were randomized to one of four cohorts (200 mg QD, 200 mg BID, 400 mg QD, 600 mg BID) with 10 subjects (eight active, two placebo) in each cohort, and received treatment for 10 days. Serial HIV RNA, pharmacokinetics, and safety evaluations were performed through day 24. Of the 40 subjects, 21 were treatment-experienced; 35 were male, 20 were non-white, and eight were coinfected with hepatitis C virus. Median baseline HIV RNA ranged from 4.26log10 to 4.46 log10. 873140 was generally well tolerated with no drug-related discontinuations. The most common adverse events were grade 1 gastrointestinal complaints that generally resolved within 1–3 days on therapy. No clinically significant abnormalities were observed on electrocardiogram or in laboratory parameters. Mean log changes in HIV RNA at nadir, and the percentage of subjects with > 1 log10 decrease were −0.12 (0%) for placebo, −0.46 (17%) for 200 mg once daily, −1.23 (75%) for 200 mg twice daily, −1.03 (63%) for 400 mg once daily, and −1.66 (100%) for 600 mg twice daily. An Emax relationship was observed between the area under the 873140 plasma concentration–time curve and change in HIV RNA. 873140 demonstrated potent antiretroviral activity and was well tolerated. These results support further evaluation in Phase 2b/3 studies.Keywords
This publication has 7 references indexed in Scilit:
- The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry InhibitorMolecular Pharmacology, 2005
- Prospects of HIV‐1 entry inhibitors as novel therapeuticsReviews in Medical Virology, 2004
- The prevalence of antiretroviral drug resistance in the United StatesAIDS, 2004
- The CCR5 and CXCR4 Coreceptors—Central to Understanding the Transmission and Pathogenesis of Human Immunodeficiency Virus Type 1 InfectionAIDS Research and Human Retroviruses, 2004
- Prospective Randomized Trial of Emtricitabine versus Lamivudine Short‐Term Monotherapy in Human Immunodeficiency Virus–Infected PatientsThe Journal of Infectious Diseases, 2003
- Use of a Small Molecule CCR5 Inhibitor in Macaques to Treat Simian Immunodeficiency Virus Infection or Prevent Simian–Human Immunodeficiency Virus InfectionThe Journal of Experimental Medicine, 2003
- Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected PersonsJAMA, 2002